Table 3 Baseline clinical characteristics of the final study cohorts
Characteristic | Confirmed HAE (n = 254) | Suspected HAE (n = 1299) |
|---|---|---|
Comorbidity, n (%) | Â | Â |
 Allergy/anaphylaxis | 61 (24.0) | 498 (38.3) |
 Hypertension | 50 (19.7) | 276 (21.2) |
 Anxiety | 28 (11.0) | 125 (9.6) |
 Arthritis | 26 (10.2) | 94 (7.2) |
 Depression | 22 (8.7) | 116 (8.9) |
 Diabetes | 22 (8.7) | 102 (7.9) |
 Urticaria | 21 (8.3) | 164 (12.6) |
 Obesity | 20 (7.9) | 149 (11.5) |
 Anemia | 17 (6.7) | 118 (9.1) |
 Hypothyroidism | 17 (6.7) | 73 (5.6) |
 COPD | 9 (3.5) | 103 (7.9) |
 Fluid and electrolyte disorders | 8 (3.1) | 57 (4.4) |
 Liver disease | 3 (1.2) | 36 (2.8) |
 Pruritus | 3 (1.2) | 37 (2.8) |
 Hypotension | 2 (0.8) | 18 (1.4) |
Prescriptions for HAE-specific medication | ||
 Patients with ≥ 1 prescription, n (%) | 23 (9.1) | 13 (1.0) |
 Prescriptions PPPM |  |  |
  Mean (SD) | 0.10 (0.11) | 0.10 (0.08) |
  Median (IQR) | 0.08 (0.03–0.13) | 0.05 (0.04–0.14) |
 Type of treatment, n (%) |  |  |
  C1 inhibitor | 8 (3.1) | 2 (0.2) |
  Ecallantide | 0 | 0 |
  Icatibant | 4 (1.6) | 1 (0.1) |
  Androgen | 15 (5.9) | 11 (0.8) |
HAE attack diagnosis and/or procedure codes | ||
 Patients with evidence of ≥ 1 HAE attack, n (%) | 115 (45.3) | 683 (52.6) |
 HAE attacks PPPM |  |  |
  Mean (SD) | 0.03 (0.05) | 0.04 (0.04) |
  Median (IQR) | 0.02 (0.00–0.04) | 0.02 (0.01–0.05) |